tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Instil Bio’s Axion discontinues clinical development of AXN-2510
PremiumThe FlyInstil Bio’s Axion discontinues clinical development of AXN-2510
3M ago
Instil Bio reports Q3 EPS ($1.75) vs ($2.55) last year
Premium
The Fly
Instil Bio reports Q3 EPS ($1.75) vs ($2.55) last year
4M ago
Instil Bio’s AXN-2510 Study: A Promising Step in Cancer Treatment
Premium
Company Announcements
Instil Bio’s AXN-2510 Study: A Promising Step in Cancer Treatment
5M ago
Instil Bio Receives Buy Rating Amid Promising Trial Data and Strong Financial Outlook
PremiumRatingsInstil Bio Receives Buy Rating Amid Promising Trial Data and Strong Financial Outlook
7M ago
Instil Bio Reports Promising Phase 2 Study Results
Premium
Company Announcements
Instil Bio Reports Promising Phase 2 Study Results
8M ago
Instil Bio: ImmuneOnco reports results from Phase 2 study of IMM2510/AXN-2510
Premium
The Fly
Instil Bio: ImmuneOnco reports results from Phase 2 study of IMM2510/AXN-2510
8M ago
Instil Bio Elects Director and Ratifies Auditor
PremiumCompany AnnouncementsInstil Bio Elects Director and Ratifies Auditor
10M ago
Instil Bio Advances Phase 2 Trial in China
Premium
Company Announcements
Instil Bio Advances Phase 2 Trial in China
10M ago
Biotech Alert: Searches spiking for these stocks today
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
10M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100